Australia markets closed
  • ALL ORDS

    7,249.70
    +27.20 (+0.38%)
     
  • ASX 200

    7,048.60
    +23.80 (+0.34%)
     
  • AUD/USD

    0.6437
    +0.0006 (+0.09%)
     
  • OIL

    90.77
    -0.94 (-1.02%)
     
  • GOLD

    1,864.60
    -14.00 (-0.75%)
     
  • Bitcoin AUD

    42,008.04
    +219.60 (+0.53%)
     
  • CMC Crypto 200

    579.66
    +0.90 (+0.15%)
     
  • AUD/EUR

    0.6085
    +0.0003 (+0.05%)
     
  • AUD/NZD

    1.0725
    -0.0051 (-0.48%)
     
  • NZX 50

    11,296.43
    +118.40 (+1.06%)
     
  • NASDAQ

    14,715.24
    +12.48 (+0.08%)
     
  • FTSE

    7,608.08
    +6.23 (+0.08%)
     
  • Dow Jones

    33,507.50
    -158.84 (-0.47%)
     
  • DAX

    15,386.58
    +63.08 (+0.41%)
     
  • Hang Seng

    17,809.66
    +436.63 (+2.51%)
     
  • NIKKEI 225

    31,857.62
    -14.90 (-0.05%)
     

Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023

F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd

Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June.

Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC):

Developing new treatment options for people with blood cancers

  • Extended follow-up data for Columvi® (glofitamab) of almost two years (20 months) from the pivotal phase II NP30179 study, further investigating the potential of fixed-duration Columvi to provide durable responses in people with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)

  • Early data from the phase Ib NP40126 study of Columvi in combination with Polivy plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) in previously untreated DLBCL. These data support Roche’s overall goal to develop combination treatments with Polivy® (polatuzumab vedotin) and its CD20xCD3 bispecific antibodies, Lunsumio® (mosunetuzumab) and Columvi (glofitamab) to optimise patient outcomes

  • Subgroup analysis data from the phase III POLARIX trial of Polivy in combination with R-CHP in elderly patients with previously untreated DLBCL

Building on progress in treating liver cancer

  • Analysis of patient-reported outcomes (PROs) from IMbrave050 in adjuvant hepatocellular carcinoma (HCC), including quality of life data. These data are intended to provide a more comprehensive evaluation of the patient experience during treatment with Tecentriq® (atezolizumab) plus Avastin® (bevacizumab). IMbrave050 is the first ever phase III study in the adjuvant HCC setting to show an improvement in recurrence-free survival

  • Data from the randomised phase Ib study evaluating the investigational anti-TIGIT cancer immunotherapy tiragolumab in combination with Tecentriq plus Avastin compared with Tecentriq and Avastin alone in unresectable HCC, which will inform further clinical development for this setting

Overview of key presentations featuring Roche medicines

Medicine

Abstract title

Abstract number/presentation details

Columvi

Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a Phase Ib study

 

[NP40126 study]

#7549 poster presentation
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Monday 05 June, 2023
8:00-11:00 CT

Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal Phase II study

 

[NP30179 study]

#7550 poster presentation
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Monday 05 June, 2023
8:00-11:00 CT

Polivy

Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the Phase 3 POLARIX study

 

 

 

 

 

#7518 poster discussion
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Monday 05 June, 2023
08:00-11:00 CT (poster display)
13:15-14:45 CT (poster discussion)



Tiragolumab

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic Hepatocellular Carcinoma (uHCC)

#4010 oral abstract session
Session: Target or TIGIT in Hepatobiliary Cancer
Sunday 04 June, 2023
16:30-18:00 CT

Tecentriq

Efficacy, safety and patient-reported outcomes (PROs) from the Phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

#4002 oral abstract session
Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Friday 02 June, 2023
08:00-11:00 CT

About Roche in Oncology
Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, fluorouracil, to patients in 1962. Roche’s commitment to developing innovative medicines and diagnostics for cancers remains steadfast. The Roche Group’s portfolio of innovative cancer medicines includes: Alecensa®(alectinib); Avastin®(bevacizumab); Columvi®(glofitamab); Cotellic®(cobimetinib); Erivedge®(vismodegib); Gavreto®(pralsetinib); Gazyva®/Gazyvaro®(obinutuzumab); Herceptin®(trastuzumab); Kadcyla®(trastuzumab emtansine); Lunsumio®(mosunetuzumab); MabThera®/Rituxan®(rituximab); Perjeta®(pertuzumab); Polivy®(polatuzumab vedotin); Tarceva®(erlotinib); Rozlytrek®(entrectinib); Tecentriq®(atezolizumab); Venclexta®/Venclyxto®(venetoclax) in collaboration with AbbVie; Xeloda®(capecitabine); Zelboraf®(vemurafenib). Furthermore, the Roche Group has a robust investigational oncology pipeline focusing on new therapeutic targets and novel combination strategies. For more information on Roche’s approach to cancer, visit www.roche.com.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Investor Relations

 

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com

Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com

 

 

Investor Relations North America

 

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

 

 

Attachment